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BDDCSAbstract The aim of this commentary is to investigate the interplay of Biopharmaceutics Classiﬁ-
cation System (BCS), Biopharmaceutics Drug Disposition Classiﬁcation System (BDDCS) and Sal-
ivary Excretion Classiﬁcation System (SECS). BCS ﬁrst classiﬁed drugs based on permeability and
solubility for the purpose of predicting oral drug absorption. Then BDDCS linked permeability
with hepatic metabolism and classiﬁed drugs based on metabolism and solubility for the purpose
of predicting oral drug disposition. On the other hand, SECS classiﬁed drugs based on permeability
and protein binding for the purpose of predicting the salivary excretion of drugs. The role of metab-
olism, rather than permeability, on salivary excretion is investigated and the results are not in agree-
ment with BDDCS.
Conclusion: The proposed Salivary Excretion Classiﬁcation System (SECS) can be used as a
guide for drug salivary excretion based on permeability (not metabolism) and protein binding.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Theoretical background and interplay
Drug effective permeability is a major key factor in its trans-
port across all body membranes such as membranes in the
intestine, liver, blood capillaries, blood brain barrier and sali-
vary mucosa. An interesting ﬁnding was noted that when drugeffective permeability is high in the intestinal mucosa, it will
undergo high metabolism in the liver (Wu and Benet, 2005).
Similarly, when drug effective permeability is high in the intes-
tinal mucosa, it will undergo salivary excretion in the salivary
mucosa (Idkaidek and Arafat, 2012).
BCS ﬁrst classiﬁed drugs based on permeability and solubil-
ity for the purpose of predicting oral drug absorption as shown
in Table 1. (Amidon et al., 1995), where high intestinal perme-
ability corresponds to fractional absorption Fa > 0.9 and high
solubility corresponds to the highest oral dose being soluble in
250 ml water. Then BDDCS linked permeability with hepatic
metabolism and classiﬁed drugs based on metabolism and sol-
ubility for the purpose of predicting oral drug disposition as
shown in Table 2 (Wu and Benet, 2005). BDDCS uses liver
metabolism instead of permeability, since drug metabolism
data are more available and consistent than permeability data,
Table 2 Biopharmaceutics Drug Disposition Classiﬁcation
System (BDDCS) according to drug metabolism and solubility
(Cs).
Class Parameter
Metabolism Cs
Class I High High
Class II High Low
Class III Low High
Class IV Low Low
Table 3 Salivary Excretion Classiﬁcation System (SECS)
according to drug permeability (Peff) and fraction unbound to
plasma proteins (fu).
Class Parameter
Peﬀ Fu Salivary excretion
Class I High High Yes
Class II Low High Yes
Class III High Low Yes
Class IV Low Low No
Table 4 SECS, BCS and BDDCS interplay.
Drug fu Peﬀ · 104
(cm/s)
Azithromycin 0.71 (H) 29.74
Sitagliptin 0.62 (H) 13.75
Tolterodine 0.37 (H) 10.74
Carbamazepine 0.24 (H) 20.0
Erythromycin 0.31 (H) 36.68
Fluconazole 0.89 (H) 13.15
Norﬂoxacin 0.68 (H) 10.85
Paracetamol 0.99 (H) 74.33
Metformin 0.99 (H) 1.44
HCT 0.33 (H) 0.16
Cinacalcet 0.03 (L) 44.16
Cloxacillin 0.05 (L) 10.04
Rosuvastatin 0.1 (L) 32.15
Phenytoin 0.1 (L) 10.51
Tamsulosin 0.01 (L) 0.71
Montelukast 0.01 (L) 1.13
Lornoxicam 0.1 (L) 0.39
Losartan 0.01 (L) 1.11
Diacerhein 0.01 (L) 0.84
Ibuprofen 0.01 (L) 1.35
a E: extensively metabolized (>70%); P: poorly metabolized (<30%),
Table 1 Biopharmaceutics Classiﬁcation System (BCS)
according to drug permeability (Peff) and solubility (Cs).
Class Parameter
Peﬀ Cs
Class I High High
Class II High Low
Class III Low High
Class IV Low Low
80 N.M. Idkaidekwhere high metabolism drugs have extraction ratios >70%
and low metabolism drugs have extraction ratios <30%. It
was found that 27 out of 29 high permeability drugs (93.1%)
were highly metabolized in the liver, with few unexplained
exceptions (Benet et al., 2008).
On the other hand, SECS classiﬁed drugs based on perme-
ability and protein binding for the purpose of predicting the
salivary excretion of drugs as shown in Table 3. (Idkaidek
and Arafat, 2012). Similar to Biopharmaceutics Classiﬁcation
System BCS, Salivary Excretion Classiﬁcation System (SECS)
high intestinal permeability that corresponds to fraction
absorption Fa > 0.9. On the other hand, high protein binding
corresponds to low fraction unbound fu of <0.1 (Idkaidek
and Arafat, 2012).
The role of metabolism, rather than permeability, on
salivary excretion is investigated and the results are not in
agreement with BDDCS. It was found that only 10 out of 20
(50%) high permeability drugs were highly metabolized in
the liver as shown in Table 4.
2. Conclusion
From the regulatory point of view, the US FDA guidance for
industry stated that ‘‘The statutory deﬁnitions of BA and BE,
expressed in terms of rate and extent of absorption of the
active ingredient or moiety to the site of action, emphasize
the use of pharmacokinetic measures in an accessible biologi-
cal matrix such as blood, plasma, and/or serum to indicate re-
lease of the drug substance from the drug product into the
systemic circulation’’ (Guidance for industry: bioavailability
and bioequivalence studies for orally administered drug prod-
ucts – general considerations, 2003). Hence, the proposed Sal-
ivary Excretion Classiﬁcation System (SECS) can be used as a
guide for drug salivary excretion based on permeability (not
metabolism) and protein binding.Fa Liver metabolisma SECS class
1.00 (H) E I
1.00 (H) P I
0.99 (H) E I
1.00 (H) E I
1.00 (H) E I
1.00 (H) P I
0.99 (H) P/E I
1.00 (H) E I
0.83 (L) P II
0.18 (L) P II
1.00 (H) E III
0.99 (H) P III
1.00 (H) P III
0.99 (H) E III
0.58 (L) E IV
0.75 (L) E IV
0.38 (L) E IV
0.75 (L) E IV
0.65 (L) E IV
0.81 (L) E IV
as obtained from Ref. Custodio et al. (2008) or drug monographs.
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